Advanced Thymic Cancer Treated with Carboplatin and Paclitaxel in a Patient Undergoing Hemodialysis

作者：Miura Satoru; Kagamu Hiroshi^*; Sakai Takehito; Nozaki Koichiro; Asakawa Katsuaki; Moro Hiroshi; Okajima Masaaki; Watanabe Satoshi; Yamamoto Suguru; Iino Noriaki; Goto Shin; Kazama Junichiro James; Yoshizawa Hirohisa; Narita Ichiei

来源：Internal Medicine, 2015, 54(1): 55-58.

DOI：10.2169/internalmedicine.54.3484

• thymic cancer
• hemodialysis
• carboplatin
• paclitaxel

A 53-year-old man with an asymptomatic anterior mediastinal tumor undergoing hemodialysis was referred to our institution. He was diagnosed with thymic basaloid carcinoma based on the findings of a chest tomography-guided biopsy and successfully treated with carboplatin (300 mg/m(2)/day) and paclitaxel (200 mg/ m2/day) on day 1 for six three-week cycles. To our knowledge, this is the first report regarding the efficiency of a carboplatin dose-definition method based on the body surface area with paclitaxel in a hemodialysis patient. This report may therefore be useful for treating hemodialysis patients who are candidates for carboplatin and paclitaxel therapy.

• 出版日期2015